-

Smiths Medical Announces Launch of Portex® EchoGlo® Peripheral Nerve Block Portfolio

Inspired Engineering for Enhanced Visualization

MINNEAPOLIS--(BUSINESS WIRE)--Smiths Medical, a leading medical device manufacturer, is excited to announce the launch of its EchoGlo® peripheral nerve block portfolio. This addition to the Portex® portfolio of pain management products offers customers a complete solution for regional anesthesia from pump to patient.

The Portex® EchoGlo® needle has been engineered for echogenic brightness under ultrasound even at extreme angles, which can enhance visualization and accuracy in delivering medication. This proprietary technology helps clinicians to confidently place local anesthetic, which may reduce post-operative dependency on opioids1.

“Smiths Medical is proud to offer EchoGlo® nerve block needles as part of our patient to pump solution. Combining the echogenic brightness of EchoGlo® products with our CADD® pump portfolio provides a full solution for our clinicians and patients,” said Jaimie Mattson, Senior Director, Global Product Management at Smiths Medical.

The launch of the full EchoGlo® portfolio enables Smiths Medical to offer clinicians more solutions to treat their patients safely and effectively.

For more information about our new EchoGlo® portfolio visit https://www.smiths-medical.com/products/pain-management/peripheral-nerve-block--plexus-anesthesia/echoglo-peripheral-nerve-block-needle.

1Valdivieso, Ronald MD. “Peripheral Nerve Blocks.” Anesthesia Secrets, 4th Ed., 2011, pp.466-471

About Smiths Medical

A leading supplier of specialized medical devices and equipment for global markets, focusing on the medication delivery, vital care and safety devices market segments. For more information, visit www.smiths-medical.com.

About Smiths Group

A global technology company that has been operating for nearly 170 years, delivering products and services for the medical technology, security & defence, general industrial, energy and space & commercial aerospace markets worldwide. Smiths Group plc employs c. 23,000 colleagues in over 50 countries and is listed on the London Stock Exchange. For more information visit www.smiths.com.

Contacts

Ashley Voge
763-383-3111
media.relations@smiths-medical.com

Smiths Medical

LSE:SMIN
Details
Headquarters: Minneapolis, MN
CEO: JehanZeb Noor
Employees: 8000
Organization: OTH

Release Summary
Smiths Medical announces the launch of its Portex® EchoGlo® peripheral nerve block portfolio.
Release Versions

Contacts

Ashley Voge
763-383-3111
media.relations@smiths-medical.com

Social Media Profiles
More News From Smiths Medical

Smiths Medical Issues Worldwide Notification Regarding the Recall of Jelco® Hypodermic Needle-Pro® Fixed Needle Insulin Syringe With Skewed Graduation Markings

MINNEAPOLIS--(BUSINESS WIRE)--SMITHS MEDICAL ISSUES WORLDWIDE NOTIFICATION OF RECALL OF JELCO® HYPODERMIC NEEDLE-PRO® FIXED NEEDLE INSULIN SYRINGE WITH SKEWED GRADUATION MARKINGS...

Smiths Medical and Ivenix Partner to Revolutionize Infusion Management with First-Ever Comprehensive Suite of Infusion Solutions in US Healthcare Market

MINNEAPOLIS & BOSTON--(BUSINESS WIRE)--Smiths Medical and Ivenix Partner to Revolutionize Infusion Management with First-Ever Comprehensive Suite of Infusion Solutions in the USA....

Introducing the Portex® Acapella® Choice Blue Vibratory Positive Expiratory Pressure (PEP) Therapy System

MINNEAPOLIS--(BUSINESS WIRE)--Smiths Medical, a leading medical device manufacturer, today announces the launch of the acapella® choice blue vibratory PEP therapy system....
Back to Newsroom